Last update 25 Apr 2025

SGN-15

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
BR96-Doxorubicin, cBR96-Doxorubicin Immunoconjugate, BMS-182248
+ [5]
Action
inhibitors
Mechanism
Lewis-Y antigen inhibitors(Lewis-Y antigen inhibitors), Top II inhibitors(Topoisomerase II inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 2
United States
15 Jan 2003
Recurrent Non-Small Cell Lung CancerPhase 2
United States
15 Jan 2003
Breast cancer recurrentPhase 2
United States
01 Oct 2000
Castration-Resistant Prostatic CancerPhase 2
United States
01 Oct 2000
Colorectal CancerPhase 2
United States
--
Colorectal CancerPhase 2--
Colorectal CancerPhase 2--
Non-Small Cell Lung CancerPhase 2--
Prostatic CancerPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
62
qbubwbjxne(hwlhqbfctc) = aojqxygtmn dgawvjvwsi (oaxzxoxzdp )
-
15 Jul 2004
qbubwbjxne(hwlhqbfctc) = aqzzczqmml dgawvjvwsi (oaxzxoxzdp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free